{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:53:22Z","timestamp":1791438802009,"version":"4.3.3"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omtn.2026.102946","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:26:00Z","timestamp":1777674360000},"page":"102946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model"],"prefix":"10.1016","volume":"37","author":[{"given":"Linda","family":"Sasset","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carleigh","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Rubinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debnath","family":"Maji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delcora","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie R.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1298-5797","authenticated-orcid":false,"given":"Marek M.","family":"Drozdz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Liberatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.102946_bib1","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas","volume":"79","author":"Mojsov","year":"1987","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2026.102946_bib2","doi-asserted-by":"crossref","first-page":"11880","DOI":"10.1016\/S0021-9258(18)67324-7","article-title":"Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing","volume":"261","author":"Mojsov","year":"1986","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2026.102946_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0014-5793(87)81430-8","article-title":"Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut","volume":"211","author":"Holst","year":"1987","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omtn.2026.102946_bib4","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1172\/JCI97233","article-title":"Discovery, characterization, and clinical development of the glucagon-like peptides","volume":"127","author":"Drucker","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2026.102946_bib5","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","article-title":"Mechanisms of action of glucagon-like peptide 1 in the pancreas","volume":"113","author":"Doyle","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.omtn.2026.102946_bib6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/bph.15611","article-title":"Actions of glucagon-like peptide-1 receptor ligands in the gut","volume":"179","author":"Holst","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.omtn.2026.102946_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4093\/dmj.2025.0106","article-title":"Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies","volume":"49","author":"Park","year":"2025","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.omtn.2026.102946_bib8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.omtn.2026.102946_bib9","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","article-title":"Recent updates on GLP-1 agonists: Current advancements & challenges","volume":"108","author":"Sharma","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.omtn.2026.102946_bib10","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.omtn.2026.102946_bib11","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s40262-018-0668-z","article-title":"Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist","volume":"57","author":"Hall","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.omtn.2026.102946_bib12","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2415550121","article-title":"The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity","volume":"121","author":"Friedman","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.omtn.2026.102946_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102946_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1463-1326.2009.01075.x","article-title":"The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1\u20135 studies","volume":"11","author":"Blonde","year":"2009","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.omtn.2026.102946_bib15","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.omtn.2026.102946_bib16","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.omtn.2026.102946_bib17","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"van Can","year":"2014","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.omtn.2026.102946_bib18","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102946_bib19","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.102946_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.omtn.2026.102946_bib21","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for Obesity Treatment and Diabetes Prevention","volume":"392","author":"Jastreboff","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102946_bib22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102946_bib23","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2026.102946_bib24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1021\/acsmedchemlett.8b00226","article-title":"Chemical Strategies for Half-Life Extension of Biopharmaceuticals: Lipidation and Its Alternatives","volume":"9","author":"Bech","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.omtn.2026.102946_bib25","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/dmrr.2810","article-title":"Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program","volume":"32","author":"Jendle","year":"2016","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"10.1016\/j.omtn.2026.102946_bib26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/dmrr.1080","article-title":"Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein","volume":"26","author":"Glaesner","year":"2010","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"10.1016\/j.omtn.2026.102946_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/pharmaceutics16040535","article-title":"Delivery of DNA-Based Therapeutics for Treatment of Chronic Diseases","volume":"16","author":"Sussman","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2026.102946_bib28","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3390\/pharmaceutics13111882","article-title":"In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies","volume":"13","author":"Pagant","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2026.102946_bib29","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.ymthe.2025.03.038","article-title":"DNA-based delivery of G-CSF as a durable and efficacious approach to treat severe chronic neutropenia","volume":"33","author":"Drozdz","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.102946_bib30","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1080\/22221751.2020.1787108","article-title":"In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies","volume":"9","author":"Andrews","year":"2020","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.omtn.2026.102946_bib31","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1073\/pnas.96.8.4262","article-title":"High-efficiency gene transfer into skeletal muscle mediated by electric pulses","volume":"96","author":"Mir","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.omtn.2026.102946_bib32","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/nbt0998-867","article-title":"Gene transfer into muscle by electroporation in vivo","volume":"16","author":"Aihara","year":"1998","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.102946_bib33","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","article-title":"Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India","volume":"399","author":"Khobragade","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.102946_bib34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4161\/hv.2.2.2620","article-title":"Preclinical and Clinical Safety Studies on DNA Vaccines","volume":"2","author":"Schalk","year":"2006","journal-title":"Hum. Vaccines"},{"key":"10.1016\/j.omtn.2026.102946_bib35","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1038\/s41591-025-03969-0","article-title":"Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial","volume":"31","author":"Tebas","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102946_bib36","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1172\/JCI78371","article-title":"Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight","volume":"124","author":"Baggio","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2026.102946_bib37","doi-asserted-by":"crossref","first-page":"79401","DOI":"10.18632\/oncotarget.12708","article-title":"Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtn.2026.102946_bib38","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/endo.136.8.7628397","article-title":"Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV","volume":"136","author":"Kieffer","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.omtn.2026.102946_bib39","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7\u201336)amide, peptide histidine methionine and is responsible for their degradation in human serum","volume":"214","author":"MENTLEIN","year":"1993","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.omtn.2026.102946_bib40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmet.2021.12.005","article-title":"Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1\/GIP\/GCG receptor triagonist","volume":"34","author":"Bossart","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.omtn.2026.102946_bib41","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.omtn.2026.102946_bib42","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cmet.2022.12.011","article-title":"Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist","volume":"35","author":"Benichou","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.omtn.2026.102946_bib43","first-page":"391","article-title":"Oral glucose tolerance testing","volume":"41","author":"Phillips","year":"2012","journal-title":"Aust. Fam. Physician"},{"key":"10.1016\/j.omtn.2026.102946_bib44","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1210\/jc.2006-2273","article-title":"Effect of Macronutrient Composition on Postprandial Peptide YY Levels","volume":"92","author":"Essah","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.omtn.2026.102946_bib45","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.neuroimage.2006.12.035","article-title":"Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans","volume":"35","author":"Pannacciulli","year":"2007","journal-title":"Neuroimage"},{"key":"10.1016\/j.omtn.2026.102946_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/srep25658","article-title":"Trafficking of Endogenous Immunoglobulins by Endothelial Cells at the Blood-Brain Barrier","volume":"6","author":"Villase\u00f1or","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.102946_bib47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00688950","article-title":"The mouse blood-brain barrier and blood-nerve barrier for IgG: A tracer study by use of the avidin-biotin system","volume":"68","author":"Seitz","year":"1985","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.omtn.2026.102946_bib48","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/j.1471-4159.2008.05492.x","article-title":"Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2","volume":"106","author":"Demeule","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.omtn.2026.102946_bib49","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1124\/jpet.107.131318","article-title":"Identification and Design of Peptides as a New Drug Delivery System for the Brain","volume":"324","author":"Demeule","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.omtn.2026.102946_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fcdhc.2023.1293926","article-title":"The benefits of GLP1 receptors in cardiovascular diseases","volume":"4","author":"Ferhatbegovi\u0107","year":"2023","journal-title":"Front. Clin. Diabetes Healthc."},{"key":"10.1016\/j.omtn.2026.102946_bib51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.omtn.2026.102946_bib52","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.omtn.2026.102946_bib53","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.2337\/diabetes.53.suppl_3.S205","article-title":"Chronic Exposure to GLP-1R Agonists Promotes Homologous GLP-1 Receptor Desensitization In Vitro but Does Not Attenuate GLP-1R\u2013Dependent Glucose Homeostasis In Vivo","volume":"53","author":"Baggio","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.omtn.2026.102946_bib54","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.molmet.2015.01.010","article-title":"Chronic hyperglycemia downregulates GLP-1 receptor signaling in pancreatic \u03b2-cells via protein kinase A","volume":"4","author":"Rajan","year":"2015","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.omtn.2026.102946_bib55","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2337\/db06-1033","article-title":"Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia","volume":"56","author":"Xu","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.omtn.2026.102946_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101880","article-title":"Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism","volume":"80","author":"Nunn","year":"2024","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.omtn.2026.102946_bib57","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1038\/s41467-025-59485-9","article-title":"GDF8 and activin A blockade protects against GLP-1\u2013induced muscle loss while enhancing fat loss in obese male mice and non-human primates","volume":"16","author":"Mastaitis","year":"2025","journal-title":"Nat. Commun."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:15:38Z","timestamp":1791436538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126001174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2162253126001174"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102946","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.05.30.656889","asserted-by":"object"}]},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102946"}}